HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Skinny’ US FDA User-Fee Reauthorization Would Omit Cosmetics, Supplement Regulation Reforms

Executive Summary

Cosmetics and dietary supplement program reforms may have to wait if Republican Sen. Burr's stripped-down version of US FDA user-fee reauthorization package – which tracks with companion legislation already passed in the House – is the best Congress can do before the August recess.

You may also be interested in...



Cosmetics Industry Still Committed To Reg Modernization, But FDA User-Fee Reauthorization May Not Be Vehicle

A “clean” FDA user-fee reauthorization bill – minus cosmetics modernization provisions – could be the likeliest way forward with user-fee program funding set to elapse at the end of September, a PCPC rep suggested in an email to HBW Insight.

Misbranding Grades Coming For Compliant VMS Labeling If Found Missing From Proposed MPL

Under Senate legislation proposing mandatory listing with FDA for all supplements sold in US, a product labeled in compliance with all other agency regulations would be deemed misbranded if not registered for  proposed list.

MDUFA V: US FDA Staff Could See September Lay-Off Notices

The notices normally would go out on 1 August, but unspent user fee funds may be able to sustain work for a few weeks if the program expires.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel